Indaptus Therapeutics, Inc. has filed an 8-K report detailing significant changes in its leadership. Nir Sassi has resigned from his position as Chief Financial Officer effective April 1, 2026. The company stated that Sassi's resignation was not due to any disagreements regarding the company's operations or policies. In a move to strengthen its governance, the Board of Directors has appointed Qinglai Lu as a new member, effective April 8, 2026. Lu brings over 20 years of experience in corporate finance and asset management, having previously served as Managing Partner at Plunkett Capital. His appointment is seen as a strategic addition to the board, aligning with the company's goals for growth and operational excellence. Additionally, Yu Ding has been appointed as the new Chief Financial Officer, effective immediately. Ding has extensive experience in financial markets and has held senior positions in various companies, including Grand Auto Service Group and the Hong Kong Stock Exchange. These leadership changes are expected to have a small negative impact on the company's stock price as they may introduce uncertainty during the transition period.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.